Bagneux, France, March 6, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences.
David Schilansky, Chief Operating Officer, will present at the 2015 Barclays Global Healthcare Conference on Tuesday, March 10, 2015, at 9:00 am ET in Miami, FL. DBV will also host investor meetings at the 8th Kempen & Co Healthcare & Life Sciences Conference on Thursday, April 16, 2015, in New York, NY.
A live audio webcast of the Barclays presentation will be available on the Investor Relations section of the company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will be available on DBV's website within 48 hours after the event.
About DBV Technologies DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
|DBV Technologies Contacts|
|Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 email@example.com|| Nathalie Donne |
Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 firstname.lastname@example.org
|DBV Technologies IR and Media Contacts|
| Marion Janic |
US Media Relations
Rooney & Associates
Tél. : +1-212-223-4017
DBV to present at upcoming Investor Conferences http://hugin.info/156437/R/1900182/675297.pdf
Source: DBV Technologies